Certara (NASDAQ:CERT) Receives Market Perform Rating from William Blair

William Blair reaffirmed their market perform rating on shares of Certara (NASDAQ:CERT - Free Report) in a report published on Thursday,RTT News reports.

Other research analysts have also recently issued research reports about the stock. Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday. TD Cowen began coverage on shares of Certara in a research note on Thursday. They issued a "buy" rating and a $16.00 price objective for the company. Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, November 7th. Finally, Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $15.83.

Certara Stock Performance

NASDAQ:CERT traded down $0.04 during mid-day trading on Thursday, reaching $11.94. The company's stock had a trading volume of 1,908,118 shares, compared to its average volume of 965,527. The firm's fifty day moving average price is $12.45 and its two-hundred day moving average price is $11.63. The stock has a market cap of $1.92 billion, a P/E ratio of -59.70, a PEG ratio of 9.29 and a beta of 1.57. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $9.41 and a 12-month high of $19.87.

Remove Ads

Institutional Trading of Certara

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC increased its stake in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after purchasing an additional 2,509 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock worth $46,000 after acquiring an additional 2,076 shares during the period. Johnson Financial Group Inc. bought a new stake in shares of Certara during the fourth quarter valued at about $47,000. Finally, KBC Group NV lifted its position in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.